Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 104, Issue 3, 2010, Pages 225-229

  Rijal, S ^a   Bhandari, S ^a   Koirala, S ^a   Singh, R ^a   Khanal, B ^a   Loutan, L ^b   Dujardin, J C ^c   Boelaert, M ^c   Chappuis, F ^b  

^a B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Control programme; Kala azar; Nepal; Pentavalent antimonials; Risk factors; Therapeutic failure

Indexed keywords

AMPHOTERICIN B; ANTIMONY GLUCONATE; ANTIPROTOZOAL AGENT; STIBOGLUCONATE SODIUM;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG EFFICACY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; INDIA; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALE; NEPAL; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHILD; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; MALE; NEPAL; TREATMENT FAILURE; YOUNG ADULT;

NASO HEXACANTHUS;

EID: 77149131232     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2009.08.002     Document Type: Article

References (30)

1. Yamey G., and Torreele E. The world's most neglected diseases. BMJ 325 (2002) 176-177 Erratum. BMJ 2002;325:352
2. WHO. The leishmaniases and Leishmania/HIV co-infections. Geneva: World Health Organization; 2000. Fact sheet No. 116. http://www.who.int/mediacentre/factsheets/fs116/en/print.html [accessed 25 February 2009].
3. WHO. Manual on visceral leishmaniasis control. Geneva: World Health Organization; 1996. WHO/LEISH/96.40.
4. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6 (2001) 849-854
5. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A., et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31 (2000) 1104-1107
6. Rijal S., Chappuis F., Singh R., Bovier P.A., Acharya P., Karki B.M., et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 97 (2003) 350-354
7. Anoopa S.D., Bern C., Varghese B., Chowdhury R., Haque R., Ali M., et al. The economic impact of visceral leishmaniasis on households in Bangladesh. Trop Med Int Health 11 (2006) 757-764
8. Veeken H., Ritmeijer K., Seaman J., and Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 5 (2000) 312-317
9. Ritmeijer K., Dejenie A., Assefa Y., Hundie T.B., Mesure J., Boots G., et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43 (2006) 357-364
10. Sundar S., Thakur B.B., Tandon A.K., Agrawal N.R., Mishra C.P., Mahapatra T.M., et al. Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ 308 (1994) 307
11. Rijal S., Chappuis F., Singh R., Boelaert M., Loutan L., and Koirala S. Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg 97 (2003) 597-598
12. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180 (1999) 564-567
13. Rijal S., Yardley V., Chappuis F., Decuypere S., Khanal B., Singh R., et al. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?. Microbes Infect 9 (2007) 529-535
14. Laguna F., Lopez-Velez R., Pulido F., Salas A., Torre-Cisneros J., Torres E., et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 13 (1999) 1063-1069
15. Alvar J., Aparicio P., Aseffa A., den Boer M., Canavate C., Dedet J.P., et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21 (2008) 334-359 table of contents
16. Collin S., Davidson R., Ritmeijer K., Keus K., Melaku Y., Kipngetich S., et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 38 (2004) 612-619
17. Das V.N., Ranjan A., Bimal S., Siddique N.A., Pandey K., Kumar N., et al. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India 8 (2005) 131-133
18. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 (2002) 1739-1746
19. Bhattacharya S.K., Sinha P.K., Sundar S., Thakur C.P., Jha T.K., Pandey K., et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 196 (2007) 591-598
20. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., and Bhattacharya S.K. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356 (2007) 2571-2581
21. Alvar J., Croft S., and Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 61 (2006) 223-274
22. Respess R.A., Rayfield M.A., and Dondero T.J. Laboratory testing and rapid HIV assays: applications for HIV surveillance in hard-to-reach populations. AIDS 15 Suppl 3 (2001) S49-59
23. Chulay J.D., and Bryceson A.D. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32 (1983) 475-479
24. Thakur C.P. Socio-economics of visceral leishmaniasis in Bihar (India). Trans R Soc Trop Med Hyg 94 (2000) 156-157
25. Rijal S., Koirala S., Van der Stuyft P., and Boelaert M. The economic burden of visceral leishmaniasis for households in Nepal. Trans R Soc Trop Med Hyg 100 (2006) 838-841
26. Bhattacharya S.K., Sur D., Sinha P.K., and Karbwang J. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable. Indian J Med Res 123 (2006) 195-196
27. Boelaert M., Criel B., Leeuwenburg J., Van Damme W., Le Ray D., and Van der Stuyft P. Visceral leishmaniasis control: a public health perspective. Trans R Soc Trop Med Hyg 94 (2000) 465-471
28. Sundar S., and Murray H.W. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 83 (2005) 394-395
29. Sundar S., Rai M., Chakravarty J., Agarwal D., Agrawal N., Vaillant M., et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 47 (2008) 1000-1006
30. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27 (2004) 305-318